August 16, 2007 – Sinovac Biotech Ltd. (SVA) released a much improved financial report for the first half of 2007. In comparison with 2006, the first six months of 2007 showed sales up 189% to $13.5 million and a profit of $3.5 million. In the year earlier, the company had a loss of nearly $1 million. Its main product, an inactivated Hepatitis A vaccine called Healive, took advantage of the fact that its largest competitor is being phased out. More details...
